Search Medical Condition
Please enter condition
Please choose location

Hitachi, Ibaraki, Japan Clinical Trials

A listing of Hitachi, Ibaraki, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (7) clinical trials

A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K

This study is an extension study conducted as an open-label multicenter study in rheumatoid arthritis (RA) patients who completed the Phase IIb Study of ASP015K [015K-CL-RAJ1 (hereinafter referred to as study RAJ1)], Phase III Study of ASP015K [015K-CL-RAJ3 (RAJ3)], or Phase III Study of ASP015K [015K-CL-RAJ4 (RAJ4)]. Patients will receive ...

Phase

0.0 miles

Learn More »

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

This will be an open-label, uncontrolled study which will enroll completers from Study 31-08-250 and new subjects not participating in Studies 250. The treatment history of subjects prior to enrolment in the open-label study will vary according to the design of the pivotal double-blind study (i.e 31-08-250). This open-label study ...

Phase

0.0 miles

Learn More »

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), parallel group (each participant group receives different treatments simultaneously), event driven (the study duration is determined by the time taken for a specific number of events to ...

Phase

0.99 miles

Learn More »

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history) associated with the safety and effectiveness of evolocumab therapy for the patients with ...

Phase N/A

0.99 miles

Learn More »